-
Infection preventionists at Vanderbilt Medical Center in Nashville have developed a comprehensive glucometer cleaning protocol that other IPs may want to emulate as regulators respond to outbreaks of hepatitis B virus in diabetics and other patients.
-
A clinic in Madison, WI has contacted 2,345 patients to advise them they may have been exposed to bloodborne pathogens after finding an employee was inappropriately using insulin pens and finger stick devices during patient training.
-
The following FAQs summarize inquiries from healthcare personnel received by the Centers for Disease Control & Prevention regarding best practices for performance of assisted blood glucose monitoring and insulin administration.
-
The Centers for Disease Control and Prevention recommends the following infection prevention measures for blood glucose monitoring and insulin administration.
-
A key advisory committee to the Centers for Disease Control and Prevention is expected to recommend that millions of diabetics be immunized against hepatitis B virus, a move that could finally halt the recurrent and deadly HBV outbreaks linked to needles and devices used in glucose monitoring in a variety of healthcare settings, Hospital Infection Control & Prevention has learned.
-
There have been recurrent warnings that the United States is facing an HIV clinician shortage that could lead to a critical setback in the fight against AIDS.
-
Medical schools, HIV organizations, foundations, and the federal government will need to work together to avert a crisis as the supply of HIV-trained physicians dwindles, experts say.
-
The global AIDS response is at "a scientific watershed" that includes both dramatic recent advances against HIV and the formidable challenge of extending the benefits to impoverished nations.
-
On May 23, 2011, the Food and Drug Administration approved telaprevir (Incivek®), an hepatitis C virus (HCV) protease inhibitor. Telaprevir is the second direct acting antiviral drug against the hepatitis C virus to be approved.
-
A landmark new CDC study dubbed TDF2 along with a separate trial released July 13, 2011 provide the first evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex, the Centers for Disease Control & Prevention reports.
